Analysts Set Johnson & Johnson (NYSE:JNJ) PT at $175.93

Johnson & Johnson (NYSE:JNJ) has been given an average rating of “Moderate Buy” by the thirteen ratings firms that are currently covering the firm, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $175.93.

JNJ has been the subject of a number of recent analyst reports. TD Cowen reduced their target price on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a report on Thursday, July 18th. Sanford C. Bernstein lifted their target price on Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. TD Securities reduced their target price on Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. Morgan Stanley lifted their target price on Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a report on Wednesday, October 16th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 16th.

Insider Buying and Selling

In related news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the sale, the vice president now owns 18,973 shares in the company, valued at $3,131,683.38. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.16% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Johnson & Johnson

A number of large investors have recently bought and sold shares of the stock. Houlihan Financial Resource Group Ltd. purchased a new position in Johnson & Johnson in the 3rd quarter worth approximately $1,290,000. XML Financial LLC increased its stake in Johnson & Johnson by 1.5% in the 3rd quarter. XML Financial LLC now owns 69,117 shares of the company’s stock worth $11,201,000 after purchasing an additional 1,002 shares during the period. Sustainable Insight Capital Management LLC purchased a new position in Johnson & Johnson in the 3rd quarter worth approximately $276,000. Carr Financial Group Corp increased its stake in Johnson & Johnson by 15.6% in the 3rd quarter. Carr Financial Group Corp now owns 4,028 shares of the company’s stock worth $653,000 after purchasing an additional 543 shares during the period. Finally, GSG Advisors LLC increased its stake in shares of Johnson & Johnson by 4.5% during the third quarter. GSG Advisors LLC now owns 5,973 shares of the company’s stock valued at $968,000 after buying an additional 257 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Up 0.2 %

Shares of JNJ opened at $160.13 on Tuesday. The business has a 50-day moving average of $163.31 and a 200 day moving average of $155.51. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $168.85. The firm has a market cap of $385.53 billion, a P/E ratio of 23.17, a price-to-earnings-growth ratio of 2.84 and a beta of 0.52. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The company had revenue of $22.47 billion during the quarter, compared to analyst estimates of $22.17 billion. During the same quarter last year, the firm posted $2.66 EPS. The firm’s revenue for the quarter was up 5.2% on a year-over-year basis. As a group, research analysts forecast that Johnson & Johnson will post 9.94 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be given a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a yield of 3.10%. Johnson & Johnson’s payout ratio is 71.78%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.